<DOC>
	<DOCNO>NCT00014560</DOCNO>
	<brief_summary>RATIONALE : Antibodies locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness antibody therapy treat patient refractory relapse non-Hodgkin 's lymphoma chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Antibody Therapy Treating Patients With Refractory Relapsed Non-Hodgkin 's Lymphoma Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose dose-limiting toxicity bispecific antibody 4G7xH22 patient relapsed refractory non-Hodgkin 's lymphoma chronic lymphocytic leukemia . - Assess clinical toxicity antibody patient . OUTLINE : This dose escalation study bispecific antibody ( BsAb ) 4G7xH22 . Patients receive sargramostim ( GM-CSF ) subcutaneously day 1 BsAb 4G7xH22 IV 2 hour day 2 . Treatment repeat weekly total 3 course absence unacceptable toxicity . Cohorts 3-6 patient receive escalate dos BsAb 4G7xH22 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 6 patient experience dose-limiting toxicity . Patients follow weekly 4 week , monthly 3 month , periodically 1 year . PROJECTED ACCRUAL : Approximately 18 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis CD19+ nonHodgkin 's lymphoma chronic lymphocytic leukemia Primary refractory multiply relapse ( least 2 prior chemotherapy regimen ) disease Ineligible bone marrow peripheral blood stem cell transplantation PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : More 3 month Hematopoietic : WBC great 3,000/mm^3 Platelet count great 100,000/mm^3 Absolute neutrophil count great 1,500/mm^3 Hepatic : Bilirubin le 1.5 mg/dL Alkaline phosphatase less 2 time normal SGPT le 2 time normal Renal : Creatinine clearance great 50 mL/min Other : No humanantimurineantibody response prior murine monoclonal antibody No immunological inflammatory disease ( e.g. , lupus erythematosus ) No active serious infection No serious medical condition would limit survival less 2 year No active malignancy except nonmelanoma skin cancer carcinoma situ cervix No psychiatric addictive disorder would preclude study Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Prior immunotherapy allow Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : Concurrent steroid adrenal failure adverse reaction study drug allow Concurrent hormonal therapy nondisease relate condition ( e.g. , insulin diabetes ) allow Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
</DOC>